Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 27, 2026Sponsor estimate | NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · Hypercholesterolaemia | NVSLead | Phase 4 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy Volunteers | BMYLead | Phase 4 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 27, 2026Sponsor estimatePhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 4NCT07681076Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersKaruna Therapeutics, Inc., a Bristol Myers Squibb company · Healthy VolunteersRecruitingBMYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 4NCT04314375Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17...Bausch Health Americas, Inc. · Ulcerative ColitisRecruitingBHCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 4NCT06119061Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular DrainageAaron Cook · Subarachnoid Hemorrhage, AneurysmalRecruitingCPIXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 4NCT06967753Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral...UBATEC · HIVRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 4NCT07197762MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsEmory University · Neisseria MeningitidisRecruitingPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 4NCT07133880Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsUniversity of Tennessee Graduate School of Medicine · COPD (Chronic Obstructive Pulmonary Disease)RecruitingTBPHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2026Sponsor estimatePhase 4NCT07884175A Study of Updated mRNA Seasonal Influenza VaccinesModernaTX, Inc. · Seasonal InfluenzaRecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 4NCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT05004727Multi-Center PAMPA StudyNYU Langone Health · PsoriasisRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc. · SARS-CoV-2RecruitingMRNALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06860633Treatment of Myasthenia Gravis Exacerbation or Crisis With EfgartigimodUniversity of Colorado, Denver · Myasthenia Gravis CrisisRecruitingARGXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06862219A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerAstellas Pharma Global Development, Inc. · Metastatic Urothelial CarcinomaRecruitingPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT07600177Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyOregon Health and Science University · Hypertrophic Cardiomyopathy (HCM)RecruitingCYTKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT07606625Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye TreatmentUniversity of California, Berkeley · Dry EyeRecruitingVTRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 4NCT05598398NPWTi on Closure of Chronic Pressure SoresNorthwestern University · Pressure SoreRecruitingMMMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 4NCT06875258PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)The Netherlands Cancer Institute · Erectile Dysfunction Following Radical ProstatectomyRecruitingVTRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2, 2027Sponsor estimatePhase 4NCT07140653Arcuate Incisions With Light Adjustable Lens for Astigmatism Correction in Lens SurgeryCenter For Sight · AstigmatismRecruitingLNSRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 4NCT07813026Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational...Viatris Inc. · HealthyRecruitingVTRSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT07224529Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland DysfunctionUniversity of Alabama at Birmingham · Meibomian Gland Dysfunction (MGD) | HROWCollaborator | Phase 4 | Recruiting | Locked | Locked | Locked |
| Feb 15, 2027Sponsor estimate | NCT07138560BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's DiseaseThe Cleveland Clinic · Parkinson Disease | AMRXCollaborator | Phase 4 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 4NCT07224529Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland DysfunctionUniversity of Alabama at Birmingham · Meibomian Gland Dysfunction (MGD)RecruitingHROWCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2027Sponsor estimatePhase 4NCT07138560BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's DiseaseThe Cleveland Clinic · Parkinson DiseaseRecruitingAMRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.